跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 382 条关于
“Lanova”
全部
382
临床试验
211
药物
63
机构
53
资讯
55
去年
Sino Biopharmaceutical Acquires LaNova Medicines for $951 Million, Targeting PD-1xVEGF Cancer Therapies
去年
GI Innovation and LaNova Partner to Develop Novel Combination Therapy for Pancreatic Cancer
去年
LaNova Medicines Initiates Phase 1 Trial of LM-299, Anti-PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
去年
Sino Biopharm Acquires LaNova Medicines for $950M, Expanding Innovative Drug Pipeline
去年
Sino Biopharm Reports Strong H1 2025 Results with 27% Growth in Innovative Drug Sales and Strategic LaNova Acquisition
去年
Merck Expands Oncology Pipeline with $3.2B Deal for LaNova's Bispecific Antibody
去年
Merck Licenses Cancer Drug from LaNova, Tune Therapeutics Advances HBV Therapy, and Amgen Defends Obesity Drug
去年
Merck Expands Oncology Pipeline with $588M Acquisition of LaNova's Bispecific Antibody LM-299
去年
Merck Forges Ahead with Bispecific Antibody and Oral GLP-1 Agonist, Updates Immuno-oncology Programs
去年
Merck's Keytruda Faces New Competition in Cancer Treatment Arena
第 1 页,共 6 页
上一页
下一页